VectivBio

VectivBio is a global, clinical-stage biotechnology company dedicated to developing transformative therapies for patients with serious, rare diseases. The company focuses on researching rare diseases through well-defined biological approaches, targeting conditions that can be addressed by optimal disease-modifying therapies. These therapies have the potential to meaningfully transform and improve the lives of patients and their families, rather than merely offering incremental improvements or benefiting from standard care. VectivBio's lead program, apraglutide, is a next-generation GLP-2 analog for the treatment of Short Bowel Syndrome (SBS).